Literature DB >> 8737125

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses.

R Wise1, D Honeybourne.   

Abstract

There are a number of potential sites of infection in the lower respiratory tract. This review summaries the nature of these sites and the ways in which antibiotic penetration can be studied. The results of a single-dose and a multiple-dose study of the penetration of sparfloxacin into the respiratory tract are also provided. After a single oral dose of sparfloxacin 400 mg or a 400 mg loading dose on day 1 followed by 200 mg daily for 2 days, sparfloxacin concentrations in the bronchial mucosa, epithelial lining fluid and alveolar macrophages were higher than the corresponding concentrations in serum. Compared with other fluoroquinolones, sparfloxacin achieves higher concentrations at these sites. Sparfloxacin diffusion into maxillary sinus mucosa has been studied in patients with chronic maxillary sinusitis undergoing surgery. High concentrations of sparfloxacin were detected in sinus mucosa 2 to 5 h after administration of a single dose of sparfloxacin 200 or 400 mg.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737125     DOI: 10.1093/jac/37.suppl_a.57

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.

Authors:  Drosos E Karageorgopoulos; Konstantina P Giannopoulou; Alexandros P Grammatikos; George Dimopoulos; Matthew E Falagas
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

Review 3.  Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Authors:  Sungmin Kiem; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

4.  Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

Authors:  J A Schrickx; J Fink-Gremmels
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

5.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 6.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  Disposition kinetics of sparfloxacin in healthy, hepatopathic, and nephropathic conditions in chicken after single intravenous administration.

Authors:  M K Bhar; S Khargharia; A K Chakraborty; T K Mandal
Journal:  Indian J Pharmacol       Date:  2009-06       Impact factor: 1.200

Review 9.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

10.  Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

Authors:  L J Piddock; M Johnson; V Ricci; S L Hill
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.